Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
September 29, 2021
Date of Patent:
December 5, 2023
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Jens Hukelmann, Heiko Schuster, Ricarda Hannen, Christoph Schraeder, Jens Fritsche, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor
Abstract: Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against T-cell immunoglobulin mucin receptor 3 (TIM3). Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals receiving cancer vaccines and/or checkpoint inhibitor treatment.
Type:
Grant
Filed:
January 28, 2022
Date of Patent:
September 12, 2023
Assignee:
NantBio, Inc.
Inventors:
Clifford Anders Olson, Kayvan Niazi, Hermes J. Garban, Raymond Wong, Shiho Tanaka
Abstract: Nucleic acid molecules that include a nucleotide sequence encoding a chimeric antigen receptor (CAR) and a nucleotide sequence encoding a protease sensitive scFv, wherein the chimeric antigen receptor comprises: an scFv targeting a tumor antigen, a spacer, a transmembrane domain, a co-stimulatory domain, and a CD3? signaling domain; and the protease-sensitive scFv and the scFv target the same tumor antigen are described.
Type:
Grant
Filed:
January 25, 2019
Date of Patent:
July 18, 2023
Assignee:
City of Hope
Inventors:
Xiuli Wang, Stephen J. Forman, Lawrence Stern, Christine E. Brown, Joseph Cohen
Abstract: Monoclonal antibodies that specifically bind the F1 antigen of Yersinia pestis with high affinity are described. Use of the monoclonal antibodies for the detection of Y. pestis infection and the diagnosis of plague are also described. Immunoconjugates of the monoclonal antibodies and a radionuclide can also be used for the treatment of a Y. pestis infection.
Type:
Grant
Filed:
September 25, 2020
Date of Patent:
July 18, 2023
Assignee:
Triad National Security, LLC
Inventors:
Antonietta Maria Lillo, Nileena Velappan, Armand Earl Ko Dichosa, Stosh Anthony Kozimor, Laura Margaret Lilley
Abstract: Provided in the present invention is an anti-5T4 antibody-drug conjugate and the use thereof. In particular, provided in the present invention is an anti-5T4 antibody-drug conjugate. Also provided in the present invention are the pharmaceutical use of the anti-5T4 antibody-drug conjugate and the effect thereof in inhibiting or preventing tumors.
Type:
Grant
Filed:
January 8, 2018
Date of Patent:
June 20, 2023
Assignee:
HANGZHOU ADCORIS BIOPHARMA CO., LTD.
Inventors:
Zhenwei Miao, Tong Zhu, Alisher B. Khasanov, Sheldon Cao, Zhaohui Li, Min Wu
Abstract: Disclosed herein is a monoclonal antibody or a derivative thereof that specifically binds to human plasmalemma vesicle-associated protein (PLVAP, PV-1), including antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody light chain variable region, and antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody heavy chain variable region. The invention also provides a preparation process of a human-mouse chimeric antibody and amino acid sequences of the antibody heavy chain variable region and the antibody light chain variable region. The monoclonal antibody or derivative thereof can be used as a component of a pharmaceutical composition or prepared into a suitable medicament, administered alone or combined with other medications such as anti-VEGF monoclonal antibody and the like, for treating choroidal neovascularization fundus diseases and other angiogenesis/osmosis-related diseases.
Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
Abstract: The invention provides anti-CD39 antibody compositions and their use in treating cancer.
Type:
Grant
Filed:
September 15, 2020
Date of Patent:
May 23, 2023
Assignee:
Surface Oncology, Inc.
Inventors:
Scott Chappel, Andrew Lake, Michael Warren, Austin Dulak, Erik Devereaux, Pamela M. Holland, Tauqeer Zaidi, Matthew Rausch, Bianka Prinz, Nels P. Nielson, Sonia Das, Alison M. O'Neill
Abstract: Disclosed are isolated single heavy chain variable (VHH) monoclonal antibodies, antigen binding fragments thereof, and bispecific antibodies include these VHH monoclonal antibodies, wherein the VHH monoclonal antibody or antigen binding fragment specifically binds a canine programmed death (PD)-1. Nucleic acid molecules encoding these VHH monoclonal antibodies and antigen binding fragments are also disclosed, as are expression vectors including these nucleic acid molecules and host cells including these expression vectors. Methods of detecting canine PD-1, and methods of increasing cytotoxic T cell activity and treating tumors are also disclosed.
Type:
Grant
Filed:
August 13, 2020
Date of Patent:
April 18, 2023
Assignee:
Oregon State University
Inventors:
Dan Vincent Mourich, Carl E. Ruby, Shay Bracha, Christopher Keith Cebra